A surge in the prevalence of obesity and metabolic syndrome, which promote systemic inflammation, underlies an increase in cardiometabolic disease. Free fatty acid receptor 4 is a nutrient sensor for long-chain fatty acids, like ω3-polyunsaturated fatty acids (ω3-PUFAs), that attenuates metabolic disease and resolves inflammation. Clinical trials indicate ω3-PUFAs are cardioprotective, and this review discusses the mechanistic links between ω3-PUFAs, free fatty acid receptor 4, and attenuation of cardiometabolic disease.
Keywords: 18-hydroxyeicosapentaenoic acid (18-HEPE); cardiometabolic disease; free fatty acid receptor 4 (Ffar4); heart; specialized proresolving mediators (SPM); ω3-polyunsaturated fatty acids (ω3-PUFAs).